Aethlon Medical (NASDAQ:AEMD) Coverage Initiated at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report released on Monday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Aethlon Medical in a research note on Monday, March 10th.

Aethlon Medical Trading Up 2.2 %

NASDAQ AEMD opened at $0.36 on Monday. The business has a fifty day simple moving average of $0.44 and a 200 day simple moving average of $0.49. Aethlon Medical has a 12 month low of $0.24 and a 12 month high of $1.79. The firm has a market capitalization of $5.77 million, a P/E ratio of -0.23 and a beta of 1.71.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.09. As a group, sell-side analysts predict that Aethlon Medical will post -0.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AEMD. Allegiance Financial Group Advisory Services LLC purchased a new stake in Aethlon Medical during the fourth quarter valued at about $26,000. Virtu Financial LLC bought a new stake in shares of Aethlon Medical in the fourth quarter valued at approximately $81,000. Renaissance Technologies LLC purchased a new stake in shares of Aethlon Medical during the 4th quarter valued at approximately $25,000. Sassicaia Capital Advisers LLC bought a new position in Aethlon Medical in the 4th quarter worth approximately $31,000. Finally, Boothbay Fund Management LLC purchased a new position in Aethlon Medical in the 4th quarter valued at approximately $186,000. Institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.